Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been observed, i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: Wang, Dongxu, Lin, Jianzhen, Yang, Xu, Long, Junyu, Bai, Yi, Yang, Xiaobo, Mao, Yilei, Sang, Xinting, Seery, Samuel, Zhao, Haitao
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6480748/
https://ncbi.nlm.nih.gov/pubmed/31014381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0730-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky